Compare FVRR & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FVRR | CGEM |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 754.2M | 671.7M |
| IPO Year | 2019 | 2021 |
| Metric | FVRR | CGEM |
|---|---|---|
| Price | $21.43 | $10.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $32.60 | $27.14 |
| AVG Volume (30 Days) | 727.8K | ★ 1.2M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 139.40 | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $427,401,000.00 | N/A |
| Revenue This Year | $12.77 | N/A |
| Revenue Next Year | $5.67 | N/A |
| P/E Ratio | $35.46 | ★ N/A |
| Revenue Growth | ★ 12.68 | N/A |
| 52 Week Low | $19.36 | $5.68 |
| 52 Week High | $36.11 | $13.60 |
| Indicator | FVRR | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 51.47 | 58.44 |
| Support Level | $20.43 | $10.01 |
| Resistance Level | $21.37 | $13.33 |
| Average True Range (ATR) | 0.63 | 1.10 |
| MACD | 0.19 | 0.04 |
| Stochastic Oscillator | 76.39 | 48.98 |
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Wiring and Translation, and Video and Animation among others.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.